Literature DB >> 23534772

Lack of any association between blood groups and lung cancer, independent of histology.

Arzu Oguz1, Dilek Unal, Arzu Tasdemir, Samet Karahan, Fatma Aykas, Hasan Mutlu, Yasemin Benderli Cihan, Mehmet Kanbay.   

Abstract

INTRODUCTION: Lung cancer, the leading cause of cancer deaths, is divided into 2 main classes based on its biology, therapy and prognosis: non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Many cases are at an advanced stage at diagnosis, which is a major obstacle to improving outcomes. It is important to define the high risk group patients for early diagnosis and chance of cure. Blood group antigens are chemical components on erythrocyte membranes but they are also expressed on a variety of epithelial cells. Links between ABO blood groups with benign or malignant diseases, such as gastric and pancreas cancers, have been observed for a long time. In this study, we aimed to investigate any possible relationship between lung cancer histological subtypes and ABO-Rh blood groups.
MATERIALS AND METHODS: The files of 307 pathologically confirmed lung cancer patients were were reviewed retrospectively. Cases with a serologically determined blood group and Rh factor were included and those with a history of another primary cancer were excluded, leaving a total of 221. The distribution of blood groups of the lung cancer patients were compared with the distribution of blood groups of healthy donors admitted to the Turkish Red Crescent Blood Service in our city in the year 2012.
RESULTS: There was no significant difference between patients with lung cancer of either type and the control group in terms of distribution of ABO blood groups and Rh factor (p: 0.073). There was also no relationship with non small cell cancer histological subtypes.
CONCLUSIONS: In this study, we found no relationship between the ABO-Rhesus blood groups and NSCLC and SCLC groups. To our knowledge this is the first analysis of ABO blood groups in SCLC patients.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23534772     DOI: 10.7314/apjcp.2013.14.1.453

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  10 in total

1.  Glioblastoma and ABO blood groups: further evidence of an association between the distribution of blood group antigens and brain tumours.

Authors:  Mohammed Z Allouh; Mohammed M Al Barbarawi; Mohammad Y Hiasat; Mohammed A Al-Qaralleh; Emad I Ababneh
Journal:  Blood Transfus       Date:  2016-06-30       Impact factor: 3.443

2.  Association of ABO blood groups with von Willebrand factor, factor VIII and ADAMTS-13 in patients with lung cancer.

Authors:  Xia Liu; Xiaogang Chen; Jiezuan Yang; Renyong Guo
Journal:  Oncol Lett       Date:  2017-07-20       Impact factor: 2.967

Review 3.  Hemostasis, cancer, and ABO blood group: the most recent evidence of association.

Authors:  Giancarlo Maria Liumbruno; Massimo Franchini
Journal:  J Thromb Thrombolysis       Date:  2014       Impact factor: 2.300

4.  Is Human Kallikrein 11 in Non-small Cell Lung Cancer Treated Chemoradiotherapy Associated with Survival?

Authors:  Dilek Unal; Celalettin Eroglu; Arzu Tasdemir; Hatice Karaman; Neslihan Kurtul; Arzu Oguz; Sema Sezgin Goksu; Bunyamin Kaplan
Journal:  Cancer Res Treat       Date:  2015-03-13       Impact factor: 4.679

Review 5.  The role of the histoblood ABO group in cancer.

Authors:  Seth K Rummel; Rachel E Ellsworth
Journal:  Future Sci OA       Date:  2016-03-15

6.  ABO blood groups as a prognostic factor for recurrence in ovarian and vulvar cancer.

Authors:  Céline Montavon Sartorius; Andreas Schoetzau; Henriette Kettelhack; Daniel Fink; Neville F Hacker; André Fedier; Francis Jacob; Viola Heinzelmann-Schwarz
Journal:  PLoS One       Date:  2018-03-29       Impact factor: 3.240

7.  Elevated serum Cripto-1 and VEGF levels in patients with non-small cell lung cancer.

Authors:  Chunhua Xu; Jue Zou; Li Li; Qi Yuan; Wei Wang
Journal:  FASEB Bioadv       Date:  2022-05-03

8.  ABO blood classification and the risk of lung cancer: A meta-analysis and trial sequential analysis.

Authors:  Haotian Yang; Ziqi Tan; Yizhen Zhang; Jiaqi Sun; Peng Huang
Journal:  Oncol Lett       Date:  2022-08-12       Impact factor: 3.111

9.  The diagnostic and prognostic value of serum human kallikrein-related peptidases 11 in non-small cell lung cancer.

Authors:  Chun-Hua Xu; Yu Zhang; Li-Ke Yu
Journal:  Tumour Biol       Date:  2014-02-09

10.  The Prevalence of Rhesus-Negative Blood Group Among Patient With Small Cell Lung Cancer and Analysis of Its Effect on Overall Survival.

Authors:  Abhishek Biswas; Yue Jiang; Danmeng Li; Hiren J Mehta; Frederic Kaye
Journal:  Front Oncol       Date:  2018-09-10       Impact factor: 6.244

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.